DSP Healthcare Fund - Growth - Regular Plan

Other Plans and Options
  • (-0.31%)Nav, as on 24-01-2020

  • Previous Nav

  • Net Change on 24-01-2020

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the scheme is to seek to generate consistent returns bypredominantly investing in equity and equity related securities of pharmaceutical and healthcarecompanies.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
S&P BSE Health Care 5.31 9.47 0.79 -1.86 -1.87 13.44

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 2.92 5.79 3.90 2.07 2,416.99
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 1.55 -2.14 -0.08 2.40 926.47
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 4.57 0.79 0.00 2.36 394.61

Fund Holdings as on 31-December-2019

  • Dr. Reddy's Laboratories Limited

  • IPCA Laboratories Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Divi's Laboratories Limited

  • Sun Pharmaceutical Industries Limited

  • Apollo Hospitals Enterprise Limited

  • Indoco Remedies Limited

  • Jubilant Life Sciences Limited

  • Max India Limited

  • Syngene International Limited

  • Procter & Gamble Health Limited

  • Torrent Pharmaceuticals Limited

  • Abbott India Limited

  • Alembic Pharmaceuticals Limited

  • Abiomed Inc

  • Alkem Laboratories Limited

  • Unichem Laboratories Limited

  • Aarti Drugs Limited

  • Abbott Laboratories

  • Ajanta Pharma Limited

  • TREPS / Reverse Repo Investments / Corporate Debt Repo

  • Dr. Lal Path Labs Ltd.

  • ICICI Lombard General Insurance Company Limited

  • Net Receivables/Payables

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Chemicals

  • Finance - Investment

  • Insurance

View More

About DSP Healthcare Fund

Scheme Analysis

DSP Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to DSP Mutual Fund. It was launched on 30-Nov-2018 and currently has an AUM of ₹243.42 crore. DSP Healthcare Fund is benchmarked against S&P BSE Health Care as primary index.

The NAV of DSP Healthcare Fund ended down ₹-0.04(-0.31%)yesterday to ₹11.742.

Among its top 3 holdings the fund has exposure to Dr. Reddy's Laboratories Limited, and

The DSP Healthcare Fund is managed by Vinit Sambre and Jay Kothari.

Fund House Contact

Mafatlal Centre, 10th Floor, Nariman Point, Mumbai - 400 021

+91 (22) 66578000
+91 (22) 66578181

Fund Manager

  • Education:B.Com, FCA
  • Experience:14 years
  • Basic Details:Mr.Vinit Sambre has 14 Years of Experience in Mutual Fund Industry. He joined DSPBRIM in July 2007, as Portfolio Analyst for the firm's PMS division. Previously, he was with DSP Merrill Lynch as a part of its Global Private Client business. He spent 20 months at DSP Merrill Lynch as Equity Strategist. Prior to DSP Merrill Lynch, he was employed with IL&FS Investsmart Limited as an Equity Analyst in their PMS division. Prior to that, he has worked with UTI Investment Advisory Services as Equity Analyst for the offshore fund - India Growth Fund. Vinit is a Chartered Accountant from Institute of Chartered Accountant of India (Nov'1997).
  • Funds Managed:
  • DSP Healthcare Fund
  • DSP Midcap Fund
  • DSP Healthcare Fund
  • DSP Midcap Fund
  • Education:B.Com, M Sc Finance, MBA
  • Experience:
  • Basic Details:Aditya has worked across the world, including in the US, EU, Latin America and in India. He started his career working with Glenmark Pharma in 2005 and worked in Brazil and Argentina. He then moved to Lehman Brothers(US) in 2007 and covered US generics companies like Teva, Mylan etc. He then worked with Nomura (UK) in 2008, covering MNC Pharma companies like GSK,Novartis, Sanofi among others, moving to Nomura India in 2011, where he started coverage of Indian Healthcare sector. Aditya joined DSP in 2015. He has an MSc.(Finance), PGDM (MDI,Gurgaon),CIIA (UK),CFA (ICFAI).
  • Funds Managed:
  • DSP Healthcare Fund
  • DSP Healthcare Fund

  • Cash

  • Equity

View More